Press Release PR9.NET
Home Submit Press Release Search Archives
Press Release
Advanced Search

Health Health
Dentistry, Education
Insurance, Medicine
Mental, Nutrition
Environmental Health
Resources, Weight Loss

Business Business
Computers Computers
Entertainment Entertainment
Games Games
Home Home
Science Science
Sports Sports
Society Society
Teens Teens
Press Release Category Health - Medicine - TheraVitae Co., Ltd. Release Date: January 17, 2005

The Scientific Advisory Board of Theravite Holds Its First Meeting

By TheraVitae Co., Ltd.
January 17, 2005
Send SEND Print PRINT Download PDF Version PDF Contact TheraVitae Co., Ltd. CONTACT

The first Scientific Advisory Board (SAB) meeting of TheraVitae Ltd., innovators of a revolutionary cell therapy for severe heart disease, was held last weekend in Eilat, Israel. The Board’s medical and scientific glance toward the future is one of the most important elements in TheraVitae’s strategy to remain at the forefront of cell therapy.

PR9.NET January 17, 2005 - Bangkok, Thailand and Rehovot, Israel - Chaired by Prof. Alex Battler, Chairman of Cardiology at the Sackler Faculty of Medicine, Tel Aviv University, Israel, the Board is composed of eminent scientists and physicians including Prof. Aaron J. Ciechanover, the 2004 Nobel Prize Laureate for biochemistry and Prof. John Marshall, one of the inventors of the Excimer Laser for the treatment of refractive eye disorders.

Other members of the SAB are:

• Prof. Michael Belkin, Director Ophthalmic Technologies Laboratory at Tel Aviv University,
• Prof. Supachai Chaithiraphan, Chairman of the ASEAN Heart Association and President of the Heart Association of Thailand,
• Prof. Ren-Ke Li, senior scientist at the Toronto General Research Institute, one of the pioneers of cardiac cell therapy,
• Prof. Naphtali Savion, the Past President of the Tel Aviv University Eye Research Institute.

During the meeting, topics related to the ongoing clinical trials as well as future research projects were presented by the Company's scientists and physicians. The members of the SAB and the additional guests who also included Dr. Amit Patel from the University of Pittsburgh and Dr. Stanley Kurtz expressed their satisfaction with the encouraging interim results of the clinical trial.

The trial, which is ongoing in Thailand and whose Principal Investigator is Prof Damras Tresukosol, Head of the Catheterization Laboratory at the Siriraj Hospital, Bangkok, is assessing the safety and efficacy of the administration of a cellular therapy composed of endothelial progenitor cells (cells with the potential of growing blood vessels) to patients suffering from severe angina pectoris. The cellular product is manufactured from the patient's own cells according to a patented process developed by TheraVitae.

Another session of the meeting was dedicated to new projects in development at TheraVitae. The members of the Board assessed the scientific and business potential of these future projects, guiding the Company on their prioritization and the activities that should be undertaken to develop them into viable treatments.

The members of the Board of Directors of Theravitae were also present and were able to get an overview of the exciting science and medicine developed at the Company.

"These were two exciting days", said Mr. Robert Clark, TheraVitae's Chairman, "We had a great opportunity to meet the distinguished scientists and physicians who are enabling us to chart the course of cell therapy for the foreseeable future."
Dr. Valentin Fulga, CEO of Theravitae added: "The presence and the support of all the distinguished participants at this meeting strengthen us and reinforce our confidence that we are proceeding in the right direction both scientifically and business wise."

# # #

Contact Information of TheraVitae Co., Ltd. Contact Information of TheraVitae Co., Ltd.
Phone (66) 2 6644290
FAX (66) 2 664 4289
E-Mail E-mail Address Protected
Address 36/72 PS Tower, 21st Floor, Sukhumvit 21 Rd., Klongtoey-Nua, Wattana, Bangkok 10110

About TheraVitae Co., Ltd.

TheraVitae is an emerging healthcare company focused on using the patient’s own cells to treat a variety of disorders, especially cardiovascular diseases. TheraVitae is an international company, based in Bangkok, Thailand and Kiryat Weizmann, Israel, benefiting from collaborations with eminent physicians and scientists who are affiliated with well-known medical and academic institutions.

The Company is committed to helping patients by developing and utilizing cutting-edge science at its highest standards. TheraVitae plans to launch a state-of-the-art facility for processing blood from patients in Thailand within the next year. The facility is expected to support cell-based products for Thailand and Southeast Asia and to develop protocols that exploit TheraVitae’s patented technology to treat other serious medical conditions.

Recent News Headlines
More Press Releases
Industry Category of Current Press Release
    Copyright © 2004 - 2014 PR9.NET - All rights reserved RSS Feeds Submit Press Release Terms of Service Privacy Policy